Athersys Inc. (NASDAQ:ATHX)‘s stock had its “buy” rating restated by Maxim Group in a research report issued on Wednesday. They presently have a $10.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 383.09% from the stock’s previous close.
Several other research analysts have also recently issued reports on ATHX. Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Monday, July 11th. TheStreet upgraded shares of Athersys from a “sell” rating to a “hold” rating in a report on Tuesday, May 31st.
Shares of Athersys (NASDAQ:ATHX) opened at 2.07 on Wednesday. The company’s market cap is $175.91 million. Athersys has a 1-year low of $0.94 and a 1-year high of $2.90. The stock has a 50 day moving average of $1.97 and a 200 day moving average of $2.19.
Athersys (NASDAQ:ATHX) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. Athersys had a negative net margin of 18.89% and a negative return on equity of 25.42%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.32 million. During the same quarter last year, the business earned ($0.05) earnings per share. The business’s revenue was up 200.0% on a year-over-year basis. On average, equities analysts forecast that Athersys will post ($0.21) EPS for the current year.
In related news, EVP John J. Harrington sold 15,000 shares of the firm’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $1.96, for a total value of $29,400.00. Following the completion of the sale, the executive vice president now owns 619,639 shares of the company’s stock, valued at $1,214,492.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.90% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. acquired a new stake in shares of Athersys during the second quarter worth approximately $261,000. A.R.T. Advisors LLC raised its stake in shares of Athersys by 2.5% in the second quarter. A.R.T. Advisors LLC now owns 69,953 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,715 shares during the last quarter. State Street Corp raised its stake in shares of Athersys by 1,932.0% in the second quarter. State Street Corp now owns 1,046,480 shares of the biopharmaceutical company’s stock worth $2,272,000 after buying an additional 994,980 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Athersys during the second quarter worth approximately $161,000. Finally, Teachers Advisors Inc. acquired a new stake in shares of Athersys during the second quarter worth approximately $258,000. 17.76% of the stock is owned by institutional investors.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.